Qui est avec moi?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wish I could have an entire banana creme pie every day for breakfast, an entire blueberry pie every day for lunch, an entire dutch apple pie every day for dinner and two entire german chocolate cakes every night for a bedtime snack without gaining any weight.
Just wishing for it or if somebody tells me it can be done doesn't mean it's gonna happen.
Exceptionally well written; grammatically, punctually and with good syntax.
Undeniably true.
The most falsehoodedness.
More false.
False.
a) NNVC never "collaborated" with USAMRIID and
b) the relationship, whatever it was, evaporated just like every other "collaboration" NNVC has had with any other testing lab.
This is another example of the absurd ill-drawn conclusion that if one company in a sector is successful then all companies in that sector will also be successful.
I remember, in days of yore, there was more than one poster here who lauded the fact that Seymour and Diwan got paid well for what they did. In fact, there were several posts that claimed they were severely underpaid.
Circumstances (no product, no revenue, big payout for Diwan) have not changed one lick since then.
Personally, I would feel extremely guilty about drawing a salary of hundreds of thousands of dollars each year for something I had not yet delivered on.
Typically, but not always (government workers and tenured educators, for example), compensation is based on performance. Shouldn't the Good Doctors consider reducing their compensation until they actually prove the science by delivering a product that generates revenue?
Furthermore, I am under no illusions that anything I say here will, in any way, affect the SP of NNVC. I am not a paid detractor. If I knew how to become one, I'd seriously consider changing professions.
I do like to believe, though, that my comments may have a certain capacity to temper some of the outlandish claims many of the Longs have made and continue to make.
I believe there are people whose resentments against NNVC supersede their compassion for humanity.
Perhaps resentment will dissipate when/if it is actually proven that NNVC benefits humanity.
Diwan must have some serious plans in the short term to be raising all this capital, now up to around $75MM. You have to think the smile on his face is massive, thinking about all that new revenue flowing from NNVC to Theracour to him. And that his collaborator, Meeta, is privy to the entire scheme.
In jest, the truth will out.
U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus Drug Development Efforts
SHELTON, CONNECTICUT -- Monday, April 6, 2020 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a leader in the development of highly effective antiviral drugs based on a novel, patented, nanomedicines platform, reports that U.S. Senator Richard Blumenthal visited the Company's facility in Shelton, Connecticut, on Tuesday, March 31, 2020.
The Honorable Senator Blumenthal visited the Company to receive an update regarding the coronavirus drug development program and to tour the cGMP-capable manufacturing facility. The Senator, his staff, and members of the Press participated in a tour of the Company's lab and manufacturing facility.
Following the tour, the Senator held a press conference in front of the building.
"NanoViricides, Inc. must be given full and fair consideration for CARES funding because every approach that has strong potential for developing a treatment for COVID-19 must be supported immediately - it will save American lives. I am going to ask my staff in Washington, DC to do whatever we can to enable the Company to access such funding and I will do everything in my power to help NanoViricides get the attention and review they merit from BARDA, the FDA and other federal agencies," assured Senator Blumenthal.
Anil R. Diwan, PhD, President and Executive Chairman of the Company, welcomed the Senator and gave a brief overview of the Company's approach to coronavirus drug development to the Press. "We are developing what is effectively a 'Venus-Fly-Trap' for the virus particle. Just as a fly is attracted to a Venus-Fly-Trap flower, and then the flower closes onto it, our material attracts the virus particle, and then wraps around the virus particle thereby rendering the virus particle incapable of infecting cells," said Dr. Diwan, adding, "Our material, i.e., a nanoviricide, mimics the human cell surface receptors to attract the virus."
"The beauty of this technology is that, a virus would not be able to escape a nanoviricide by mutations or genomic changes, because no matter how much it changes, the mutated virus still lands on the same cellular receptor in the same fashion as its earlier version," elaborated Ms. Meeta R. Vyas, SB, MBA, the Chief Financial Officer of the Company.
"I co-authored the $8.3 Billion CARES act to support the development of drugs, diagnostics, vaccines, and other measures to combat COVID-19," said Senator Blumenthal, adding, "The drug development by NanoViricides deserves to be supported."
In response to questions from reporters, Dr. Diwan explained that the Company had already identified some drug candidates that had strong activity against at least two coronaviruses that use different cellular receptors. One of these viruses uses the same receptor, namely ACE2 (angiotensin-converting enzyme 2), as SARS-CoV-2, the coronavirus that causes COVID-19 disease.
This broad-spectrum activity provides confidence that these candidates would be effective against SARS-CoV-2, he emphasized. Testing against SARS-CoV-2 itself is expected to be performed very soon. The Company is in the process of setting up collaborations with external BSL3/BSL4 labs that have developed assays for such testing, he added. Dr. Diwan also stated that the Company intends to publish its results once the verification experiments are completed. In parallel, the Company has already begun certain animal studies to help identify clinical drug candidates against SARS-CoV-2, in order to expedite the program.
When asked to comment on other drugs being considered to treat the virus, Dr. Diwan explained that the nanoviricides technology was complementary to other drugs because nanoviricides attack the virus outside the cell to prevent it from infecting the cell, while other drugs (except antibodies) work inside the cell to reduce virus replication. "A nanoviricide drug for attacking the virus particle and stopping the re-infection cycle taken together with another drug for limiting viral replication inside cells would make an even more effective treatment for COVID-19 than either one by itself," he explained.
"We can produce sufficient quantities of a drug to treat as many as a thousand patients in a single batch in our cGMP-compliant manufacturing facility," said Dr. Diwan, in response to a question from a reporter regarding manufacturing capacity of the Company adding, "The manufacturing capacity can be substantially increased with additional resources."
"We have been working on this project with limited internal resources while continuing our work on our lead drug against Shingles which is close to an IND," said Dr. Diwan. He added, "At this stage, we need help from government agencies, laboratories, and collaborators to quickly deliver our promising potential treatment to patients suffering from COVID-19. It is an honor to have Senator Blumenthal visit our facility. We are grateful for his commitment to assist us in accessing potential federal funding and agency support, from the likes of the Biomedical Advanced Research and Development Authority (BARDA), the FDA and the NIH, in our effort to save American lives in the fierce battle our country faces to defeat SARS-CoV-2."
About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company has previously worked on developing drug candidates against the MERS coronavirus. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this press release are forward-looking statements, including, but not limited to, the company's proposed follow-on offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the company cautions investors that actual results may differ materially from the anticipated results. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to Investigational New Drug application.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
MJ Clyburn
TraDigital IR
clyburn@tradigitalir.com
HEADLINE: NNVC's Diwan Rows Against Virus in Exchange for Profiting on the Pandemic.
Confucius say: one who invests in NNVC, funds the Diwan/Vyas empire for generations, yet divests oneself of any profit.
Confucius say: bad exposure is usually not good exposure.
Confucius say: He who relies on self-published Facebook feeds when considering investing decisions would be better served taking up macrame or badminton.
NNVC 0,0875 $USD, 27.07.2020 close
NanoViricides: A History Of Producing Headlines Without Producing A Product
https://seekingalpha.com/article/4320921-nanoviricides-history-of-producing-headlines-without-producing-product
Maybe not.
NanoViricides Announces Patent Awards in Australia
http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Announces%20Patent%20Awards%20in%20Australia.html
NanoViricides Announces Patent Awards in Australia
WEST HAVEN, CONNECTICUT --Wednesday, March 24, 2014 -- NanoViricides, Inc. (NYSE MKT: NNVC) announced today that a fundamental PCT patent application, on which the nanoviricides® technology is based, has resulted in additional issued patents in Australia and the Philippines.
"The issuance of the Australian patent is of particular importance because of the Company's interest in pursuing the initial human clinical trials in that country," said Eugene Seymour, MD, MPH, CEO of the Company, adding, "Australia offers significant advantages including financial incentives that would help us speed the development of our drugs towards licensure".
The Australian and Philippine patents have been allowed with a very broad range of claims to a large number of families of chemical structure compositions, pharmaceutical compositions, methods of making the same, and uses of the same.
NanoViricides, Inc. holds exclusive, perpetual, worldwide licenses to these technologies for a broad range of antiviral applications and diseases (see below).
"It is rewarding to see that both the Australian and Philippine patent offices recognized the novelty and the broad utility of the entire 'pi-polymer' class of materials as defined by the inventors, and granted a patent with sufficient scope to protect the whole of the invention, for all foreseeable pharmaceutical applications," said Dr. James Demers, PhD, JD, Gotham Patent Services LLC, who represents the inventors and directs the international patenting effort. He further added, "In addition, the inventors have also filed an original PCT application that covers the nanoviricides® anti-viral substances."
These compositions result in self-assembling polymers that we call "TheraCour®" polymers (or "pi-polymers"), and possess significant advantages over the earlier block-copolymer systems, hard nanoparticle systems, as well as liposomal and emulsion systems, that are now advancing in nanomedicines development.
The TheraCour polymers result in polymeric micelles that can be used to encapsulate active pharmaceutical ingredients (APIs) to develop superior drugs where needed. Of greater importance to NanoViricides, they are capable of direct targeting to any desired surface with defined specificity, such as a virus particle.
The current first generation nanoviricides® drug candidates have achieved very high levels of effectiveness only by employing the specific targeting ability of the TheraCour polymer systems. These first generation drugs did not require encapsulation of any additional APIs to achieve their high levels of effectiveness. The Company believes this has simplified the drug approval process for us, because the specifically targeted nanoviricide polymer we make is itself the drug in these cases.
In addition, with this technology, the Company has the ability to develop drugs against intractable viral diseases wherein very little virus may be present in circulation. In such cases, the Company can employ the approach of encapsulating multiple antiviral APIs that act by orthogonal mechanisms, and deliver the payload specifically to infected cells by using ligands that bind preferentially to infected cells. Drug combinations are known to often provide enhanced synergistic effectiveness, and have been approved in viral diseases such as HIV/AIDS and Hepatitis C. The encapsulation approach is known to be superior to the simple formulated "fixed drug" combinations approach that is being employed at present. Nevertheless, fixed drug combinations result in the conventional approach of attacking all cells, and are not restricted to attacking infected cells preferentially, and thus are expected to be relatively toxic. Our next generation nanoviricides approach is anticipated to require significant further development and resources. The Company is therefore focusing at present on its wide drug pipeline of six antiviral projects, namely injectable FluCide™, oral FluCide™, DengueCide™, HerpeCide™, HIVCide™, and the broad-spectrum drug for viral diseases of the external eye.
In addition to this basic PCT application that covers the "pi-polymer" structure itself, another PCT application that discloses making antiviral agents from the TheraCour family of polymers and such structures is in various stages of prosecution in several countries, and has already issued in at least seven countries and regions.
The original "pi-polymer" international application was filed under the Patent Cooperation Treaty (PCT) system in 2006. Several other patents have already been granted previously in this patent family in various countries and regions, including Canada, Europe, Israel, ARIPO, China, HongKong, Japan, Mexico, New Zealand, OAPI, Vietnam and South Africa, and the USA. Prosecution in several other countries continues.
The patents are being issued to the inventors Anil R. Diwan, PhD, Jayant G. Tatake, PhD, and Ann L. Onton, all of who are among the founders of NanoViricides, Inc. The patents have been assigned to AllExcel, Inc., the Company at which the ground-breaking work was performed. AllExcel, Inc. has contractually transferred this intellectual property to TheraCour Pharma, Inc.
NanoViricides, Inc. holds exclusive, worldwide, perpetual, licenses from TheraCour Pharma, Inc. to these technologies and patents for a broad range of antiviral applications and diseases that include all Influenzas including Asian Bird Flu Virus, Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Dengue viruses, Rabies virus, Ebola/Marburg viruses, Japanese Encephalitis virus, as well as viruses causing viral Conjunctivitis (a disease of the eye) and ocular herpes.
About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
FDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.
Contact:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
EX-10.12 3 ex10_12.htm EXHIBIT 10.12
https://www.sec.gov/Archives/edgar/data/1379006/000114036107006096/ex10_12.htm
EX-10.12 3 ex10_12.htm EXHIBIT 10.12
Dec 23, 2005
To
Nguyen Tran Hien, MD, MPH, PhD
Director
National Institute of Hygiene and Epidemiology (NIHE)
1 Yersin Street
Hanoi, Viet Nam
Dear Dr. Hien:
Enclosed please find a Memorandum of understanding between NanoViricides, Incorporated, USA, and NIHE, Viet Nam, as per our discussions for the purposes of cooperation between NanoViricides, Inc., and NIHE for novel nanotechnology-based prevention strategies, therapies and diagnostics strategies for Influenza A subtype H5N1,
We look forward to a fruitful cooperation in many areas.
Sincerely,
/s/Anil R. Diwan
Anil R. Diwan, Ph.D.
President & Chairman
NanoViricides, Inc.
Mobile: 203-606-9180
email: adiwan@nanoviricides.com
or adiwan@snet.net
cc:
Dang Duc Anh, PhD
Vice Director, NIHE.
135 Wood Street, Ste. 205, West Haven, CT 06516, USA.
Memorandum of Understanding
Between
NIHE, Viet Nam and NanoViricides, Inc., USA
NANOVIRICIDES, INC. 135 Wood Street, Suite 205, West Haven, CT 06516, and National Institute of Hygiene and Epidemiology (NIHE), 1 Yersin Street, Hanoi, Viet Nam, agree to enter into a scientific research cooperation on the development of prevention, diagnostics, and therapeutic strategies for Influenza A subtype H5N1, including:
*
Research on Novel Nanotechnology-based Vaccines (NanoVaccines),
*
Research on Novel Nanotehnology-based Therapies (NanoViricides), and
*
Research on Novel Nanotechnology-based Diagnostics,
It Is understood that these development projects will begin as small projects. As success Is achieved, the projects can be continued for further development.
These various strategies are based on the nanotechnology intellectual property and products of NanoViricides, Inc.
NanoViricides, Inc. shall retain all intellectual property rights to resulting products and technologies and shall make full efforts for world-wide protection of such intellectual property rights.
Certain rights for the new nanotechnology products and technologies develop shall be provided to NIHE for use in Viet Nam.
The work plan, costs budget, compensation and financial responsibilities of each party to the projects shall be determined in the final Agreement.
It Is understood that both parties will be sharing confidential information and intellectual property of the other party, and will ensure that such information is protected to its fullest and not publicly disclosed except by written consent from the other party when so decided.
Signed: December 23, 2005 by both parties at NIHE, Hanoi, Viet Nam
/s/ Nguyen Tran Hien
/s/ Anil R. Diwan
Professor Nguyen Tran Hien, MD, MPH, PhD
Anil R. Diwan, Ph.D.
Director
President & Chairman
National Institute of Hygiene and Epidemiology
Nanoviricides, Inc.
1 Yersin Street
135 Wood Street, Ste. 205
Hanoi, Viet Nam
West Haven, CT 06516, USA.
Page 1 of 1
NNVC 0,0879 $USD, 24.07.2020 10:34 am
https://smallcapsdaily.com/disclaimer/
DISCLAIMER
Small Caps Daily profiles are not a solicitation or recommendation to buy, sell or hold securities. Small Caps Daily is a paid advertiser and is not offering securities for sale. Neither Small Caps Daily nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by Small Caps Daily its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.
Small Caps Daily does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.
Information presented by Small Caps Daily may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.
THIS SITE IS PROVIDED BY Small Caps Daily ON AN “AS IS” AND “AS AVAILABLE” BASIS. Small Caps Daily MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.
TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, Small Caps Daily DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. Small Caps Daily DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM Small Caps Daily ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. Small Caps Daily, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.
CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS.
By using Small Caps Daily, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable.
The website contains links to other related World Wide Web Internet sites and resources. Small Caps Daily is not responsible for the availability of these outside resources, or their contents, nor does Small Caps Daily endorse nor is Small Caps Daily responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall Small Caps Daily be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.
You agree to indemnify and hold Small Caps Daily, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification.
Small Caps Daily is owned and operated by Stocksparq LLC, which is a US based corporation. We are paid advertisers, who disseminate information (this “Article”) about publicly traded companies (the “Profiled Issuers”).
We publish the Information on our website, smallcapsdaily.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign.
The Information we publish in the Campaign is only a snapshot about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.
All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.
We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.
The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.
We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.
We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.
There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.
We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares may sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.
We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.
We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.
We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.
Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.
The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.
If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.
SmallcapsDaily.com, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time.
Please Note: SmallCapsDaily.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.SmallCapsDaily.com the “Site”) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), SmallCapsDaily.com, a financial news media and PR marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. SmallCapsDaily.com has been compensated five thousand dollars for financial news dissemination and pr services by a third party non affiliate for solar integrated roofing corp. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. SmallCapsDaily.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news PR media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. SmallCapsDaily.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. SmallCapsDaily.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. SmallCapsDaily.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by SmallCapsDaily.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by SmallCapsDaily.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: https//www.SmallCapsDaily.com
For further information:
Media Contact: info@smallcapsdaily.com
NNVC 0,095 $USD, 24.07.2020 9:14 am
http://nanoviricides.com/proactive%20video/index.html
[click image to start video]